TUTakayuki Ueno

Takayuki Ueno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takayuki Ueno has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.

    by Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, Masahiro Kashiwaba, Naruto Taira, Masato Takahashi, Hiroshi Tada, Koichiro Tsugawa, Tatsuya Toyama, Naoki Niikura, et al.

    TPS636 Background: Combination of pertuzumab (Pmab) with trastuzumab (Tmab) has dramatically improved patients’ outcomes compared to Tmab as 1st line therapy in HER2-positive (+ve) locally advanced (LA)/metastatic breast cancer (MBC). However, it is unclear whether reexposure to this dual HER2-blockade is more effective than conventional treatment in HER2+ve LA/MBC patients previously receiving Pmab, Tmab, and chemotherapy (CT). Methods: Trial design: PRECIOUS (NCT02514681) is a multicenter randomized open-label phase III study enrolling HER2+ve LA/MBC patients pretreated with Pmab, Tmab, and CT. Patients are randomized 1:1 to receive CT of physician’s choice (docetaxel, paclitaxel, nab-paclitaxel, vinorelbine, or eribulin) plus Tmab with or without Pmab. Eligibility criteria: Patients received Pmab, Tmab, and CT for HER2+ve LA/MBC as 1st and/or 2nd line anti-HER2-containing CT. The latest regimen before enrollment does not include Pmab. The number of previous CT regimens for LA/MBC does not exceed three. Aims: The primary endpoint is investigator-assessed progression-free survival (PFS). Secondary endpoints include independent reviewer-assessed PFS, PFS in patients treated with T-DM1 as the latest regimen, response rate, duration of response, overall survival, safety, and patient-reported outcome. Translational researches using blood samples are also planned to find prognostic and predictive markers for patients receiving anti-HER2 treatment. Statistics: PFS between control arm (Tmab and CT) and experimental arm (Pmab, Tmab, and CT) will be compared using a log-rank test. Three-hundred and seventy patients will be enrolled that allow the observation of 325 events for 80% power to detect a hazard ratio of 0.739 at one-side 5% level of significance. Accrual status: Recruitment began in August 2015 and is expected to be completed in July 2018 in Japan. Clinical trial information: NCT02514681.

  • Open Access

    Breast MR Image Fusion by Deformable Implicit Polynomial (DIP)

    by Bo Zheng, Ryo Ishikawa, Jun Takamatsu, Katsushi Ikeuchi, Takaaki Endo, Kiyohide Sato, Takayuki Ueno, Tomoharu Sugie, Masakazu Toi, Shotaro Kanao, et al.

    MR Image fusion is desired in various image-guide breast surgeries. However it often suffers from the difficulty on dealing with large deformation of breast. This paper presents a novel method for efficiently modeling and inferring the physical parameters, including gravity, Young's modulus, Poisson's ratio, etc, which are important elements for handling the biomechanical deformations of breast with finite element model. Our method consists of two major steps: 1) deformation modeling and 2) non-rigid registration. The former builds a deformable implicit polynomial (DIP) model to encode the physical parameters according to deformation. The latter fast registers the prior DIP to the online breast image such that the image fusion can be achieved. Experimental results demonstrate the good performance of our method.


  • Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy

    by Kazuna Takeda, Shotaro Kanao, Tomohisa Okada, Masako Kataoka, Takayuki Ueno, Masakazu Toi, Hiroshi Ishiguro, Yoshiki Mikami, Kaori Togashi


  • Genome-wide copy number analysis in primary breast cancer

    by Takayuki Ueno, Mitsuru Emi, Hidenori Sato, Noriko Ito, Mariko Muta, Katsumasa Kuroi, Masakazu Toi

    Introduction: Carcinogenesis is considered to be a multistep process that may involve cumulative genomic alterations. Loss of chromosomal material would inactivate tumor suppressor genes and gain of chromosomal material has the potential to activate tumor-promoting genes. Areas covered: Recent intensive studies by array comparative genomic hybridization (aCGH) have demonstrated frequent alterations in multiple regions of the genome. This suggests that these regions contain a variety of oncogenes and tumor suppressor genes associated with breast cancer development. The patterns of copy number variations (CNVs) have been suggested to be associated with breast cancer subtypes, indicating the importance of genomic instability in the development of breast cancer. Expert opinion: To further clarify the complexity of gene alterations, one approach is to employ a CNV-targeted platform that harbors a large number of direct CNV markers located in the repeat-rich unstable regions of the human genome. Next generation sequencing is another approach to overcome the limitations of aCGH such as the repeat-rich regions. Genomic analysis should be combined with expression analysis to elucidate individual genes relevant to breast cancer development and progression. The elucidation of the functions of the affected genes would lead to identification of new molecular targets for breast cancer eradication.


  • Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients

    by Arwa M. Ali, Takayuki Ueno, Sunao Tanaka, Masahiro Takada, Hiroshi Ishiguro, Ashraf Z. Abdellah, Masakazu Toi


  • A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy

    by Haruko Takuwa, Takayuki Ueno, Hiroshi Ishiguro, Yoshiki Mikami, Shotaro Kanao, Masahiro Takada, Tomoharu Sugie, Masakazu Toi

    Patients with metaplastic breast cancer (MBC) exhibit reduced response to chemotherapy and have poor prognosis. We investigated a case of MBC that showed a positive response to preoperative chemotherapy, resulting in near pathological complete response (pCR). A 59-year-old woman complained of a lump in her right breast. Magnetic resonance imaging (MRI) showed the presence of a solid mass that was 24 mm in diameter. The pathological diagnosis was MBC with cartilaginous differentiation. The clinical stage was T2N0M0, stage IIA according to the International Union against Cancer (UICC) criteria. To observe the response to chemotherapy, we gave her preoperative chemotherapy. The patient was monitored closely, since we realized that failure of chemotherapy carries a risk of tumor progression. Evaluation was carried out using ultrasound, MRI, fluorodeoxyglucose (FDG) positron emission tomography (PET), and a Ki-67 labeling index after the first cycle of chemotherapy, and ultrasound after each additional cycle. FDG-PET showed a positive response after the first cycle of chemotherapy. The patient underwent 4 cycles of docetaxel (75 mg/m2) and cisplatin (75 mg/m2) followed by 4 cycles of cyclophosphamide (500 mg/m2), doxorubicin (50 mg/m2), and cisplatin (50 mg/m2). Ultrasound showed decreases in tumor size after each cycle of chemotherapy. After chemotherapy, MRI showed nearly complete regression of the tumor. Partial mastectomy was performed. Pathological examination showed few cancer cells remaining, indicating near pCR. We report a case of MBC that responded well to platinum-based preoperative chemotherapy. We propose that preoperative chemotherapy may be an option for treatment of MBC in conjunction with careful monitoring.


    • 1 June 2010
      • Vol. 57  (2) , 165-75

    Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients.

    by Kazumi Horiguchi, Masakazu Toi, Shin-Ichiro Horiguchi, Masahiro Sugimoto, Yasuhiro Naito, Yukiko Hayashi, Takayuki Ueno, Shinji Ohno, Nobuaki Funata, Katsumasa Kuroi, et al.

    We investigated the significance of CD24 and CD44 expression for predicting responses to chemotherapy and prognosis in primary breast cancer patients. Diagnosis of breast cancer was confirmed by core needle biopsy, and immunohistochemical studies were performed. Preoperatively, patients received anthracycline-containing chemotherapy. Expression of CD44 and CD24 was assessed immunohistochemically and the relationship with chemotherapy response and with prognosis was analyzed. Between 2001 and 2004, 139 women were enrolled in this study. In the correlation analysis, CD24 expression was negatively associated with pathological response to chemotherapy (p = 0.0003). A machine learning technique with an alternating decision tree (ADTree) showed that four logical rules are involved in predicting the response depending on the combination of CD24, HER2, tumor stage, CD44, progesterone receptor, and patient age. In the survival analysis, patients having CD44 (++) showed a significantly favorable prognosis as compared with others (p = 0.0002). A multivariate analysis showed that CD44 expression had an independent prognostic value (p < .0001). We found a significant correlation between CD44 expression and prognosis and between CD24 expression and response to chemotherapy. CD24 and CD44 expressions would be useful predictive markers, although further studies are needed.


    • 1 January 2009
      • Vol. 36  (1) , 15-20

    [Biomarker].

    by Takayuki Ueno, Masakazu Toi

    Biomarkers play important roles in breast cancer management, i. e. diagnosis, treatment selection, and therapeutic monitoring. While the basic treatment strategy depends on the status of hormone receptors and HER2, other molecules are intensively studied for biomarkers to predict treatment efficacies. Gene expression profiles have been developed to predict prognosis and treatment efficacies. Circulating tumor cells and endothelial cells are drawing attention for therapeutic monitoring. It is essential to understand biomarkers for the progress of personalized medicine.

    • 1 June 2008
      • Vol. 35  (6) , 987-90

    [A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide].

    by Hiroshi Yoshibayashi, Hiroshi Ishiguro, Masahiro Takada, Megumi Takeuchi, Hiroyasu Yamashiro, Takayuki Ueno, Hironori Kato, Kiyotsugu Yoshikawa, Shotaro Kanao, Chikako Yamauchi, et al.

    A 67-year-old woman visited our hospital with suspicion of right breast cancer. She underwent core needle biopsy, and her disease was diagnosed as breast cancer (invasive ductal carcinoma, ER- and PgR- positive, HER2-negative). We chose neoadjuvant chemotherapy, because the tumor size was over 3 cm in diameter and she wished to conserve her breast. She was elderly, and so without anthracycline base, we used a combination of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)) q3w 6 cycles followed by breast-conserving therapy. During treatment, the patient remained very well and showed no major side effects except grade 4 neutropenia on an outpatient basis. After 6 cycles, ultrasonography and mammography indicated the residual tumor, but breast MRI did not detect any tumor. Pathological examination showed absence of invasive tumor or only focal residual tumor cells (QpCR). We concluded that the combination of docetaxel and cyclophosphamide was a good option for neoadjuvant chemotherapy for early breast cancer.

  • The aspartic protease napsin A suppresses tumor growth independent of its catalytic activity

    by Takayuki Ueno, Göran Elmberger, Timothy E Weaver, Masakazu Toi, Stig Linder